CytomX Therapeutics, Inc. Retained Earnings
CytomX Therapeutics, Inc. (CTMX) had Retained Earnings of -$750.86 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-06
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$750.86M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$730.20M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$711.95M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$682.44M.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2026-06-30 | -$750.86M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | -$730.20M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | -$711.95M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | -$682.44M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | -$668.21M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | -$668.05M 10-Q · filed 2025-05-12 | |
| 2024-12-31 | -$691.58M 10-K · filed 2026-03-16 | |
| 2024-09-30 | -$710.46M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | -$716.19M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | -$709.66M 10-Q · filed 2024-05-08 | |
| 2023-12-31 | -$723.45M 10-K · filed 2025-03-06 | |
| 2023-09-30 | -$724.28M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | -$727.28M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | -$726.19M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | -$722.88M 10-K · filed 2024-03-11 | |
| 2022-09-30 | -$714.10M 10-K · filed 2023-03-27 | -$605.09M 10-Q · filed 2022-11-08 |
| 2022-06-30 | -$685.04M 10-K · filed 2023-03-27 | -$581.79M 10-Q · filed 2022-08-04 |
| 2022-03-31 | -$655.54M 10-K · filed 2023-03-27 | -$557.61M 10-Q · filed 2022-05-05 |
| 2021-12-31 | -$623.56M 10-K/A · filed 2023-03-27 | -$533.72M 10-K · filed 2022-03-01 |
| 2021-09-30 | -$588.74M 10-K/A · filed 2023-03-27 | -$507.50M 10-Q · filed 2021-11-04 |
| 2021-06-30 | -$557.76M 10-K/A · filed 2023-03-27 | -$484.91M 10-Q · filed 2021-08-05 |
| 2021-03-31 | -$531.02M 10-K/A · filed 2023-03-27 | -$465.67M 10-Q · filed 2021-05-06 |
| 2020-12-31 | -$507.69M 10-K/A · filed 2023-03-27 | -$450.12M 10-K · filed 2021-02-24 |
| 2020-09-30 | -$435.41M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | -$420.70M 10-Q · filed 2020-08-06 | |
| 2020-03-31 | -$405.02M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | -$442.87M 10-K/A · filed 2023-03-27 | -$417.23M 10-K · filed 2020-02-27 |
| 2019-09-30 | -$381.77M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | -$358.08M 10-Q · filed 2019-08-07 | |
| 2019-03-31 | -$329.12M 10-Q · filed 2019-05-09 | |
| 2018-12-31 | -$314.98M 10-K · filed 2020-02-27 | |
| 2018-09-30 | -$282.75M 10-Q · filed 2018-11-06 | |
| 2018-06-30 | -$259.32M 10-Q · filed 2018-08-08 | |
| 2018-03-31 | -$245.87M 10-Q · filed 2018-05-09 | |
| 2017-12-31 | -$219.47M 10-K · filed 2019-02-27 | |
| 2017-09-30 | -$220.09M 10-Q · filed 2017-11-07 | |
| 2017-06-30 | -$209.84M 10-Q · filed 2017-08-07 | |
| 2017-03-31 | -$184.62M 10-Q · filed 2017-05-05 | |
| 2016-12-31 | -$176.37M 10-K · filed 2018-03-07 | |
| 2016-09-30 | -$162.33M 10-Q · filed 2016-11-03 | |
| 2016-06-30 | -$147.67M 10-Q · filed 2016-08-03 | |
| 2016-03-31 | -$133.50M 10-Q · filed 2016-05-06 | |
| 2015-12-31 | -$117.47M 10-K · filed 2017-03-02 | |
| 2015-09-30 | -$105.98M 10-Q · filed 2015-11-23 | |
| 2014-12-31 | -$78.14M 10-K · filed 2016-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |